reports
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to ...
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS subtypes, including in those with recurrent disease Discussion of the first ever international, randomized, multicentre, double-blind, placebo-controlled phase 2 dose finding trial of Vonjo® (pacritinib) in adult patients with VEXAS syndrome WALTHAM, Mass., Oct. 25...
Lifco AB: 2 directors
Two Directors at Lifco AB bought 31,850 shares at between 374.955SEK and 380.914SEK. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
PCI Biotech update
PCI Biotech update Oslo (Norway), 23 October 2025 – PCI Biotech (OSE: PCIB) today provides an update on the ongoing evaluation of its operations. Reference is made to the company’s announcements dated 18th August 2025 and 25th September 2025, as well as the interim report for the first half of 2025 published on 29th August 2025. As previously communicated, current activities are focused on the evaluation of a new bioprocessing technology by an undisclosed party, conducted under a material transfer agreement without financial terms. The company’s limited operations and the group’s future...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
PCI Biotech update on future operations
PCI Biotech update on future operations Oslo (Norway), 25 September 2025 – PCI Biotech (OSE:PCIB) today announces an update on the ongoing evaluation of its future operations. Reference is made to the announcement on 18th August 2025 regarding the discontinuation of further development of the PCL technology. The decision was based on insufficient progress, which extended project timelines and increased resource requirements, elevating the overall project risk to an unacceptable level. Consequently, PCI Biotech decided to discontinue further development. PCI Biotech's immediate priority ha...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
PCI Biotech half-year interim 2025 report
PCI Biotech half-year interim 2025 report Oslo (Norway), 29 August 2025 – PCI Biotech (OSE: PCIB), today announces its half-yearly 2025 interim report. Please find enclosed the interim report and presentation. Highlights review OperationsPCI Biotech decided on 18th August 2025 to discontinue further development of the PCL technology. The decision was primarily based on, as described in a press release the same day, insufficient progress towards the 2025 goal of demonstrating improved net yield at mini benchtop bioreactor scale. Achieving successful results at this scale was a critical ris...
PCI Biotech: Invitation to first half 2025 results presentation and co...
PCI Biotech: Invitation to first half 2025 results presentation and corporate update Oslo, Norway, 26 August 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2025 interim report on Friday, 29 August 2025, 08:30am – 09:00am CET (local time). The presentation will be held in Norwegian as a live webcast available through There will be a Q&A session at the end of the presentation. Please submit questions to prior to the webcast. It will be possible to post written questions through the webcast console during the session. The interim report and ...
PCI Biotech announces discontinuation of development of the PCL techno...
PCI Biotech announces discontinuation of development of the PCL technology and evaluation of future operations Oslo (Norway), 18 August 2025 – PCI Biotech Holding ASA (PCI Biotech, OSE:PCIB) today announces the discontinuation of development of the photochemical lysis (PCL) technology for viral vector manufacturing. Today’s decision is primarily based on the insufficient progress towards the 2025 goal of demonstrating improved yield in mini benchtop bioreactors. Achieving successful end-to-end results in small bioreactors is a critical risk-reducing milestone for further development. Fol...
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (a...
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP) Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in children and adolescents with persistent or chronic ITP WALTHAM, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of (Sobi®), today an...
Swedish Orphan Biovitrum AB: 1 director
A director at Swedish Orphan Biovitrum AB sold 7,723 shares at 288.474SEK and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
PCI Biotech: Minutes of Annual General Meeting 2025
PCI Biotech: Minutes of Annual General Meeting 2025 Oslo, 22 May 2025. The Annual General Meeting in PCI Biotech Holding ASA took place today, 22 May 2025. All the matters on the agenda were approved and the minutes of the Annual General Meeting are attached to this release and are available on Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO / CFO, , Mobile: This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act. Attachment ...
PCI BIotech: Disclosure of voting rights for Chair of the Board
PCI BIotech: Disclosure of voting rights for Chair of the Board Oslo, 20 May 2025. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors. Hans Peter Bøhn is chair of PCI Biotech’s board of directors and shall open the annual general meeting of the Company on 22 May 2025. Mr. Bøhn holds 123,662 shares, representing 0.3 percent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 3,957,330 additional shares. In total, Mr. Bøhn will represent and vote for...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.